Combination Methotrexate and Infliximab

Ankylosing Spondylitis Clinical Trial

Official title:

The Efficacy of Combination Methotrexate and Infliximab in Patients With Ankylosing Spondylitis:A Clinical and Magnetic Resonance Imaging Correlation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00432432
• Other study ID #: AS-2005-003
• Status: Completed
• Phase: Phase 4
• First received: February 6, 2007
• Last updated: February 10, 2012
• Start date: February 2005
• Est. completion date: October 2006

Study information

• Verified date: February 2012
• Source: Chinese University of Hong Kong
• Contact: n/a
• Is FDA regulated: No
• Health authority: Hong Kong: Department of Health
• Study type: Interventional

Clinical Trial Summary

Combination Methotrexate and Infliximab:Influence of immunogenicity on the efficacy of infliximab in patients with Ankylosing Spondylitis.

Description:

Forty consecutive patients will be recruited from the rheumatology clinic of the Prince of Wales Hospital with AS meeting the modified New York criteria with active disease as defined (see below). They will be randomized to receive MTX 7.5 mg/week initially with a weekly 2.5mg increment until 15mg/week dosage is reached,( i.e by week 6) or a placebo together with folic acid 5mg daily for a period of 16 week. After 16 weeks, all patients will receive infliximab at 5 mg/kg per dose, at weeks 16, 18, and 22 (3 doses), and will continue with MTX 15 mg/week or placebo. Thereafter, they will be followed up at week 30, 38 weeks. MRI changes in the sacroiliac joints (SI) before and after infliximab treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 38
• Est. completion date: October 2006
• Est. primary completion date: August 2006
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Fulfilled the AS:meeting the modified New York criteria

• Active disease despite NSAID treatment defined as:

• Spinal inflammation ? 30 and a score of 30 on at least two of the other three domains

• Back pain

• Patient global assessment of disease activity

• Physical function

• Informed consent

Exclusion Criteria:

• Complete ankylosis of the spine

• On sulphasalazine

• Previous use of TNF inhibitors

• Multiple use of NSAIDS

• Prednisolone > 10mg/day

• Changes of NSAIDS or dose of prednisolone within 2 weeks of baseline

• Little or no ability for self-care

• Received intra-articular,intramuscular, or intravenous corticosteroids in the 4 weeks before screening

• Infected joint prosthesis during the previous 5 years

• Serious infections, such as hepatitis, pneumonia, pyelonephritis in the previous 3 months

• Any chronic infectious disease such as renal infection, chest infection with bronchiectasis or sinusitis

• Active tuberculosis requiring treatment within the previous 3 years

• Opportunistic infections such as herpes zoster within the previous 2 months

• Any evidence of active cytomegalovirus; active Pneumocystis carinii; or drug-resistant atypical mycobacterial infection

• Known hypersensitivity to murine proteins

• Current signs or symptoms of severe,progressive,or uncontrolled renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease

• A history of lymphoproliferative disease including lymphoma or signs suggestive of disease, such as lymphadenopathy of unusual size or location (ie,lymph nodes in the posterior triangle or the neck, infraclavicular epitrochlear, or periaortic areas); splenomegaly;

• Any known malignant disease except basal cell carcinoma currently or in the past 5 years.

• A hemoglobin level < 8.5 gm/dl, a white blood cell count < 3.5 × 10^9/liter, a platelet count < 100 × 10^9/liter, a serum creatinine level > 150 µmol/l, serum transaminase levels 1.25 times the upper limit of normal, or alkaline phosphatase levels > 2 times the upper limit of normal.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Ankylosing Spondylitis
• Spondylitis
• Spondylitis, Ankylosing

Intervention

Drug:
• Infliximab and MTX
MTX 15mg weekly Infliximab 5mg/kg given at day 0, wk 2, wk6

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Chinese University of Hong Kong

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The number of patient exhibited an ASAS 20 response to treatment at week 20.		wk52	Yes
Secondary	Proportion of patients with 50% and 70% improvement in disease activity.Patient global assessment of disease activity and pain;BASFI;early morning stiffness;physician global assessment of disease activity.Changes in the pre and post infusion MRI.		wk52	Yes